Navigation Links
Pharmacyclics Reports Third Quarter 2013 Results
Date:11/7/2013

Securities Exchange Act of 1934, as amended, including statements, among others, relating to our future capital requirements, including our expected liquidity position and timing of the receipt of certain milestone payments, and the sufficiency of our current assets to meet these requirements, our future results of operations, our expectations for and timing of ongoing or future clinical trials and regulatory approvals for any of our product candidates, and our plans, objectives, expectations and intentions. Because these statements apply to future events, they are subject to risks and uncertainties. When used in this announcement, the words "anticipate", "believe", "estimate", "expect", "expectation", "goal", "should", "would", "project", "plan", "predict", "intend", "target" and similar expressions are intended to identify such forward-looking statements. These forward-looking statements are based on information currently available to us and are subject to a number of risks, uncertainties and other factors that could cause our actual results, performance, expected liquidity or achievements to differ materially from those projected in, or implied by, these forward-looking statements. Factors that may cause such a difference include, without limitation, our need for substantial additional financing and the availability and terms of any such financing, the safety and/or efficacy results of clinical trials of our product candidates, our failure to obtain regulatory approvals or comply with ongoing governmental regulation, our ability to commercialize, manufacture and achieve market acceptance of any of our product candidates, for which we rely heavily on collaboration with third parties, and our ability to protect and enforce our intellectual property rights and to operate without infringing upon the proprietary rights of third parties. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future res
'/>"/>
SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related medicine technology :

1. Pharmacyclics Announces Date of Conference call to discuss Financial Results for Third Quarter Ended September 30, 2013
2. Pharmacyclics Reports Second Quarter 2013 Results
3. Pharmacyclics Announces Date of Financial Results for Second Quarter Ended June 30, 2013 and Conference Call
4. Pharmacyclics Reports First Quarter 2013 Results
5. Pharmacyclics Announces Date of Financial Results for Three Months Ended March 31, 2013 and Conference Call
6. Pharmacyclics Triggers Fourth Milestone Payment for Enrollment of 5th Patient in Frontline Phase III CLL Study
7. Pharmacyclics Announces Third Breakthrough Therapy Designation for Ibrutinib from the U.S. Food and Drug Administration
8. Pharmacyclics, Inc. Prices Public Offering of Common Stock
9. Pharmacyclics, Inc. Announces Proposed Public Offering of Common Stock
10. Pharmacyclics First to Announce Breakthrough Therapy Designation in Oncology from the U.S. Food and Drug Administration
11. Pharmacyclics Announces Date of Financial Results for Three and Six Months Ended December 31, 2012 and Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)...  Research and Markets ( http://www.researchandmarkets.com/research/6k27gw/dental ) has announced the ... Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) ... in order to treat dental impairments, for tooth restoration ...
(Date:1/15/2014)... WASHINGTON , Jan. 15, 2014 AARP Foundation today ... support older adults suffering from the severe cold weather that ... are committed to helping those in need; so to support ... dollar-for-dollar contributions up to $250,000, which could mean up to ...
(Date:1/15/2014)... , Jan. 15, 2014  Celsion Corporation (the "Company") (NASDAQ: ... commitments from institutional investors to purchase an aggregate of ... an at-the-market registered direct offering, led by a dedicated ... definitive purchase agreements with these investors pursuant to which ...
Breaking Medicine Technology:Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3
... June 22, 2007 /PRNewswire/ -- MAP,Pharmaceuticals, Inc. today ... its Unit Dose Budesonide (UDB) pediatric asthma therapy,clinical ... Lutfi Kirdar,Convention and Exhibition Center in Istanbul, Turkey. ... and safety,of a novel submicron particle formulation of ...
... Announces Bioinformatics Partnership with,Illumina , BEYOND GENOME ... a leading developer of lab and data ... announced that,it has penned an agreement with ... participant in IlluminaConnect, a,bioinformatics software program established ...
Cached Medicine Technology:MAP Pharmaceuticals to Present Unit Dose Budesonide Phase 2,Clinical Data at the World Asthma Meeting 2GenoLogics Announces Bioinformatics Partnership with Illumina 2GenoLogics Announces Bioinformatics Partnership with Illumina 3
(Date:4/17/2014)... Rochelle, NY, April 17, 2014U.S. military personnel who ... plus impact" concussive traumatic brain injury (TBI) were ... evacuated for other medical reasons. Differences in measures ... depression 6-12 months after injury are reported in ... a peer-reviewed journal from Mary Ann Liebert, Inc., ...
(Date:4/17/2014)... The cause of neuronal death in Parkinson,s disease ... neurons may be mistaken for foreign invaders and killed ... way autoimmune diseases like type I diabetes, celiac disease, ... was published April 16, 2014, in Nature Communications ... idea in Parkinson,s disease; but if true, it could ...
(Date:4/17/2014)... from Boston University School of Medicine (BUSM) have ... consumption in an experimental model. The findings, reported ... Alcohol Abuse , may lead to more effective ... is one of the leading causes of illness ... negative economic impact by limiting the productivity of ...
(Date:4/17/2014)... Spending time online has the potential to ward off ... according to research published online in The ... Sciences . In the article " Internet Use ... States: A Longitudinal Analysis ," the authors report that ... by 33 percent among their study sample. , ...
(Date:4/17/2014)... uncommon these days to find a colored ribbon representing a ... cancer. But what color ribbon does one think of with ... color, for many suffering from the disease, black may be ... study consisting of lung cancer patients, primarily smokers between the ... light on the stigma often felt by these patients, the ...
Breaking Medicine News(10 mins):Health News:Long-term effects of battle-related 'blast plus impact' concussive TBI in US military 2Health News:Is Parkinson's an autoimmune disease? 2Health News:BUSM researchers find anti-seizure drug may reduce alcohol consumption 2Health News:Internet use may cut retirees' depression 2Health News:Unraveling the 'black ribbon' around lung cancer 2
... Oxygen", as it is known by researchers at the Norwegian ... is gained on the pitch thanks to their new system ... the Journal of Sports Medicine and has enjoyed ... improve the players, sprint, jump and endurance. , "With ...
... near manufacturing industries, a breath of air may ... location, finds a recent study involving a Kansas ... of geology at Kansas State University, along with ... School of Public Health and Department of Environmental ...
... Measurement of pressure within the eye, or intraocular pressure (IOP), ... in patients with glaucoma are believed to be related to ... to the optic nerve and vision. The clinical assessment ... daytime hours. In a new study, parents using the ...
... Steven Reinberg HealthDay Reporter , TUESDAY, March ... who have psychiatric disorders, especially post-traumatic stress disorder, are ... narcotic painkillers, a new study finds. Use of ... Vicodin, can become addictive and cause more serious problems, ...
... (HealthDay News) -- Most stroke patients undergo both CT and ... rising costs of stroke care in the United States, a ... from more than 600,000 patients diagnosed with stroke between 1999 ... of the patients who had MRI scans also had CT ...
... (HealthDay News) -- When it comes to wine, a new study ... on many consumers. The professionals seem to have a much ... State University explained. As a result, wine experts are able to ... people just can,t taste. "What we found is that the ...
Cached Medicine News:Health News:1 more 'player' on the pitch thanks to a new training method 2Health News:Manganese concentrations higher in residential neighborhoods than industrial sites, varies by region 2Health News:Manganese concentrations higher in residential neighborhoods than industrial sites, varies by region 3Health News:Home measurement of eye pressure in children may improve management of glaucoma 2Health News:Narcotic Painkillers Another Threat to Traumatized War Vets: Study 2Health News:Narcotic Painkillers Another Threat to Traumatized War Vets: Study 3Health News:Brain Scans Overused on U.S. Stroke Patients, Study Says 2Health News:Wine Ratings May Be Meaningless for Most People 2
Features soft, low friction sheath that extends beyond the tip....
Designed to retain the desired curve during oral intubation....
Facilitates intubation of tracheal tubes....
SunGlide™ Stylette - Grey Child. Use in 4.0 to 7mm tubes. 25/box....
Medicine Products: